Seres therapeutics announces topline results for ser-287 phase 2b study in mild-to-moderate ulcerative colitis

Cambridge, mass.--(business wire)--seres therapeutics, inc. (nasdaq: mcrb), a leading microbiome therapeutics company, today announced topline results from the phase 2b eco-reset study evaluating ser-287 in patients with mild-to-moderate ulcerative colitis (uc). the study did not meet its primary endpoint of improving clinical remission rates compared to placebo. both dosing regimens of ser-287 were generally well tolerated. given the lack of a clinical efficacy signal identified in eco-reset,
MCRB Ratings Summary
MCRB Quant Ranking